Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.

Details

Serval ID
serval:BIB_9C0E2FAB742D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.
Journal
International Journal of Infectious Diseases
Author(s)
Wittek R.
ISSN
1201-9712 (Print)
ISSN-L
1201-9712
Publication state
Published
Issued date
05/2006
Volume
10
Number
3
Pages
193-201
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
In 1980 the World Health Organization declared that smallpox was eradicated from the world, and routine smallpox vaccination was discontinued. Nevertheless, samples of the smallpox virus (variola virus) were retained for research purposes, not least because of fears that terrorist groups or rogue states might also have kept samples in order to develop a bioweapon. Variola virus represents an effective bioweapon because it is associated with high morbidity and mortality and is highly contagious. Since September 11, 2001, countries around the world have begun to develop policies and preparedness programs to deal with a bioterror attack, including stockpiling of smallpox vaccine. Smallpox vaccine itself may be associated with a number of serious adverse events, which can often be managed with vaccinia immune globulin (VIG). VIG may also be needed as prophylaxis in patients for whom pre-exposure smallpox vaccine is contraindicated (such as those with eczema or pregnant women), although it is currently not licensed in these cases. Two intravenous formulations of VIG (VIGIV Cangene and VIGIV Dynport) have been licensed by the FDA for the management of patients with progressive vaccinia, eczema vaccinatum, severe generalized vaccinia, and extensive body surface involvement or periocular implantation following inadvertent inoculation.
Keywords
Bioterrorism, Humans, Immunization Programs/organization & administration, Immunization Programs/standards, Immunization, Passive/methods, Immunization, Passive/standards, Immunoglobulins, Intravenous/pharmacokinetics, Immunoglobulins, Intravenous/therapeutic use, Program Development, Smallpox Vaccine/adverse effects, Vaccinia/prevention & control, Vaccinia/therapy, Vaccinia virus/immunology
Pubmed
Web of science
Open Access
Yes
Create date
24/01/2008 11:43
Last modification date
20/08/2019 16:02
Usage data